Triptorelin for the treatment of endometriosis

Umberto Leone Roberti Maggiore, Carolina Scala, Valentino Remorgida, Pier Luigi Venturini, Fabio Del Deo, Marco Torella, Nicola Colacurci, Stefano Salvatore, Stefano Ferrari, Enrico Papaleo, Massimo Candiani, Simone Ferrero

Research output: Contribution to journalArticle

Abstract

Introduction: Over the past 30 years, gonadotropin-releasing hormone agonists (GnRH-a) have been used to induce a hypoestrogenic status in women with endometriosis with the aim to cause an improvement in pain symptoms similar to that observed after menopause. Triptorelin is one of the most commonly used GnRH-a. Areas covered: This review offers an explanation of the mechanism of action, of the pharmacokinetics and pharmacodynamics of triptorelin and gives the readers a complete overview of the studies on the clinical efficacy, tolerability and safety of this agent in patients with endometriosis. Expert opinion: The studies reviewed in the current manuscript demonstrate the efficacy of triptorelin in improving pain symptoms caused by endometriosis. Further, this effect is confirmed by the reduction in the volume of the endometriotic nodules during treatment. Future research should evaluate whether the pre-operative administration of triptorelin prior to surgical excision of endometriomas may be useful in preserving the ovarian reserve.

Original languageEnglish
Pages (from-to)1153-1179
Number of pages27
JournalExpert Opinion on Pharmacotherapy
Volume15
Issue number8
DOIs
Publication statusPublished - 2014

Fingerprint

Triptorelin Pamoate
Endometriosis
Gonadotropin-Releasing Hormone
Pain
Women's Rights
Manuscripts
Expert Testimony
Proxy
Therapeutics
Menopause
Pharmacokinetics
Safety

Keywords

  • Efficacy
  • Endometriosis
  • Gonadotropin-releasing hormone analogue
  • Safety
  • Triptorelin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Medicine(all)

Cite this

Leone Roberti Maggiore, U., Scala, C., Remorgida, V., Venturini, P. L., Del Deo, F., Torella, M., ... Ferrero, S. (2014). Triptorelin for the treatment of endometriosis. Expert Opinion on Pharmacotherapy, 15(8), 1153-1179. https://doi.org/10.1517/14656566.2014.916279

Triptorelin for the treatment of endometriosis. / Leone Roberti Maggiore, Umberto; Scala, Carolina; Remorgida, Valentino; Venturini, Pier Luigi; Del Deo, Fabio; Torella, Marco; Colacurci, Nicola; Salvatore, Stefano; Ferrari, Stefano; Papaleo, Enrico; Candiani, Massimo; Ferrero, Simone.

In: Expert Opinion on Pharmacotherapy, Vol. 15, No. 8, 2014, p. 1153-1179.

Research output: Contribution to journalArticle

Leone Roberti Maggiore, U, Scala, C, Remorgida, V, Venturini, PL, Del Deo, F, Torella, M, Colacurci, N, Salvatore, S, Ferrari, S, Papaleo, E, Candiani, M & Ferrero, S 2014, 'Triptorelin for the treatment of endometriosis', Expert Opinion on Pharmacotherapy, vol. 15, no. 8, pp. 1153-1179. https://doi.org/10.1517/14656566.2014.916279
Leone Roberti Maggiore U, Scala C, Remorgida V, Venturini PL, Del Deo F, Torella M et al. Triptorelin for the treatment of endometriosis. Expert Opinion on Pharmacotherapy. 2014;15(8):1153-1179. https://doi.org/10.1517/14656566.2014.916279
Leone Roberti Maggiore, Umberto ; Scala, Carolina ; Remorgida, Valentino ; Venturini, Pier Luigi ; Del Deo, Fabio ; Torella, Marco ; Colacurci, Nicola ; Salvatore, Stefano ; Ferrari, Stefano ; Papaleo, Enrico ; Candiani, Massimo ; Ferrero, Simone. / Triptorelin for the treatment of endometriosis. In: Expert Opinion on Pharmacotherapy. 2014 ; Vol. 15, No. 8. pp. 1153-1179.
@article{0b6c513ce4314c0ea3b9fca76788098f,
title = "Triptorelin for the treatment of endometriosis",
abstract = "Introduction: Over the past 30 years, gonadotropin-releasing hormone agonists (GnRH-a) have been used to induce a hypoestrogenic status in women with endometriosis with the aim to cause an improvement in pain symptoms similar to that observed after menopause. Triptorelin is one of the most commonly used GnRH-a. Areas covered: This review offers an explanation of the mechanism of action, of the pharmacokinetics and pharmacodynamics of triptorelin and gives the readers a complete overview of the studies on the clinical efficacy, tolerability and safety of this agent in patients with endometriosis. Expert opinion: The studies reviewed in the current manuscript demonstrate the efficacy of triptorelin in improving pain symptoms caused by endometriosis. Further, this effect is confirmed by the reduction in the volume of the endometriotic nodules during treatment. Future research should evaluate whether the pre-operative administration of triptorelin prior to surgical excision of endometriomas may be useful in preserving the ovarian reserve.",
keywords = "Efficacy, Endometriosis, Gonadotropin-releasing hormone analogue, Safety, Triptorelin",
author = "{Leone Roberti Maggiore}, Umberto and Carolina Scala and Valentino Remorgida and Venturini, {Pier Luigi} and {Del Deo}, Fabio and Marco Torella and Nicola Colacurci and Stefano Salvatore and Stefano Ferrari and Enrico Papaleo and Massimo Candiani and Simone Ferrero",
year = "2014",
doi = "10.1517/14656566.2014.916279",
language = "English",
volume = "15",
pages = "1153--1179",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "8",

}

TY - JOUR

T1 - Triptorelin for the treatment of endometriosis

AU - Leone Roberti Maggiore, Umberto

AU - Scala, Carolina

AU - Remorgida, Valentino

AU - Venturini, Pier Luigi

AU - Del Deo, Fabio

AU - Torella, Marco

AU - Colacurci, Nicola

AU - Salvatore, Stefano

AU - Ferrari, Stefano

AU - Papaleo, Enrico

AU - Candiani, Massimo

AU - Ferrero, Simone

PY - 2014

Y1 - 2014

N2 - Introduction: Over the past 30 years, gonadotropin-releasing hormone agonists (GnRH-a) have been used to induce a hypoestrogenic status in women with endometriosis with the aim to cause an improvement in pain symptoms similar to that observed after menopause. Triptorelin is one of the most commonly used GnRH-a. Areas covered: This review offers an explanation of the mechanism of action, of the pharmacokinetics and pharmacodynamics of triptorelin and gives the readers a complete overview of the studies on the clinical efficacy, tolerability and safety of this agent in patients with endometriosis. Expert opinion: The studies reviewed in the current manuscript demonstrate the efficacy of triptorelin in improving pain symptoms caused by endometriosis. Further, this effect is confirmed by the reduction in the volume of the endometriotic nodules during treatment. Future research should evaluate whether the pre-operative administration of triptorelin prior to surgical excision of endometriomas may be useful in preserving the ovarian reserve.

AB - Introduction: Over the past 30 years, gonadotropin-releasing hormone agonists (GnRH-a) have been used to induce a hypoestrogenic status in women with endometriosis with the aim to cause an improvement in pain symptoms similar to that observed after menopause. Triptorelin is one of the most commonly used GnRH-a. Areas covered: This review offers an explanation of the mechanism of action, of the pharmacokinetics and pharmacodynamics of triptorelin and gives the readers a complete overview of the studies on the clinical efficacy, tolerability and safety of this agent in patients with endometriosis. Expert opinion: The studies reviewed in the current manuscript demonstrate the efficacy of triptorelin in improving pain symptoms caused by endometriosis. Further, this effect is confirmed by the reduction in the volume of the endometriotic nodules during treatment. Future research should evaluate whether the pre-operative administration of triptorelin prior to surgical excision of endometriomas may be useful in preserving the ovarian reserve.

KW - Efficacy

KW - Endometriosis

KW - Gonadotropin-releasing hormone analogue

KW - Safety

KW - Triptorelin

UR - http://www.scopus.com/inward/record.url?scp=84900819944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900819944&partnerID=8YFLogxK

U2 - 10.1517/14656566.2014.916279

DO - 10.1517/14656566.2014.916279

M3 - Article

C2 - 24832495

AN - SCOPUS:84900819944

VL - 15

SP - 1153

EP - 1179

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 8

ER -